Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S

Circulation

Volumn 104, Issue 25, 2001, Pages 3046-3051

  Ballantyne, Christie M ^a   Olsson, Anders G ^b   Cook, Thomas J ^c   Mercuri, Michele F ^c   Pedersen, Terje R ^d   Kjekshus, John ^e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c MERCK RESEARCH LABORATORIES   (United States)

^d AKER UNIVERSITY HOSPITAL   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Lipids; Statins; Trials

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG RESPONSE; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035910051     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc5001.100624     Document Type: Article

References (25)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
2. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience)
3. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study: Implications for treatment
4. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The bezafibrate infarction prevention (BIP) study
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
6. Design and baseline results of the Scandinavian simvastatin survival study of patients with stable angina and/or previous myocardial infarction
7. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
8. Baseline serum cholesterol and treatment effect in the Scandinavian simvastatin survival study (4S)
9. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
10. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial
11. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
12. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
13. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas coronary atherosclerosis prevention study (AFCAPS TexCAPS)
14. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastatin survival study (4S)
15. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial
16. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy
17. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events
18. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford coronary risk intervention project
19. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian simvastatin survival study
20. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study
21. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: Relation to basal serum cholestanol
22. Introducing a new component of the metabolic syndrome: Low cholesterol absorption
23. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia
24. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters
25. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption